Advertisement
Screener

Edwards Lifesciences Corporation (EW) Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount

2.9 / 5 stars · 70/120 Roast Me

Edwards Lifesciences Corporation Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount

Edwards Lifesciences Corporation (EW) reported Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.

Financial Statements › Notes › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Annual Amount

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount · last filed 2026-02-25

  • Edwards Lifesciences Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2021-03-31 was $1.00M.
  • Edwards Lifesciences Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2020-06-30 was $1.80M.
  • Edwards Lifesciences Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2019-09-30 was $300.00K.
  • Edwards Lifesciences Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2018-06-30 was $1.70M.
  • Edwards Lifesciences Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2025 was $100.00K, a 80.00% decline from fiscal 2024.
  • Edwards Lifesciences Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2024 was $500.00K.
  • Edwards Lifesciences Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
  • Edwards Lifesciences Corporation equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2022 was $800.00K, a 80.95% decline from fiscal 2021.
Period endEquity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 3 monthEquity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 6 monthEquity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 9 monthEquity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 12 month
2025-12-31$100.00K
10-K · filed 2026-02-25
2024-12-31$500.00K
10-K · filed 2026-02-25
2024-09-30$500.00K
10-Q · filed 2024-11-06
2023-12-31$0.00
10-K · filed 2024-02-12
2022-12-31$800.00K
10-K · filed 2024-02-12
2021-12-31$4.20M
10-K · filed 2023-02-13
2021-09-30$2.60M
10-Q · filed 2021-10-29
2021-06-30$2.60M
10-Q · filed 2021-07-30
2021-03-31$1.00M
10-Q · filed 2021-04-28
2020-12-31$1.80M
10-K · filed 2022-02-14
2020-09-30$1.80M
10-Q · filed 2020-10-26
2020-06-30$1.80M
10-Q · filed 2020-07-27
$1.80M
10-Q · filed 2020-07-27
2019-12-31$300.00K
10-K · filed 2021-02-12
2019-09-30$300.00K
10-Q · filed 2019-10-25
$300.00K
10-Q · filed 2019-10-25
2018-09-30$1.70M
10-Q · filed 2018-10-26
2018-06-30$1.70M
10-Q · filed 2018-07-27
$1.70M
10-Q · filed 2018-07-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
STERIS plc (STE)Ireland$20.343B25.49
ZIMMER BIOMET HOLDINGS, INC. (ZBH)United States$17.103B20.66
ALIGN TECHNOLOGY INC (ALGN)United States$10.346B29.06
MSA Safety Inc (MSA)United States$7.023B21.47
ESTABLISHMENT LABS HOLDINGS INC. (ESTA)$1.954B-65.76
Cadre Holdings, Inc. (CDRE)United States$1.123B33.88
Enovis CORP (ENOV)United States$1.053B-1.18
Anteris Technologies Global Corp. (AVR)United States$0.746B
Sanara MedTech Inc. (SMTI)United States$0.323B-6.81
Inogen Inc (INGN)United States$0.139B-7.00